Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Dexmedetomidine alleviates neurobehavioral impairments and myelination deficits following lipopolysaccharide exposure in early postnatal rats.

Tytuł:
Dexmedetomidine alleviates neurobehavioral impairments and myelination deficits following lipopolysaccharide exposure in early postnatal rats.
Autorzy:
Wu Z; Department of Anesthesiology, Shengjing Hospital of China Medical University, Shenyang 110004, China.
Xue H; Department of Anesthesiology, Shengjing Hospital of China Medical University, Shenyang 110004, China.
Zhang Y; Department of Anesthesiology, Shengjing Hospital of China Medical University, Shenyang 110004, China.
Zhao P; Department of Anesthesiology, Shengjing Hospital of China Medical University, Shenyang 110004, China. Electronic address: .
Źródło:
Life sciences [Life Sci] 2020 Dec 15; Vol. 263, pp. 118556. Date of Electronic Publication: 2020 Oct 07.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Publication: <2008->: Amsterdam : Elsevier
Original Publication: Oxford; Elmsford, N. Y. [etc.] Pergamon Press.
MeSH Terms:
Behavior, Animal/*drug effects
Brain Injuries/*drug therapy
Dexmedetomidine/*pharmacology
Gliosis/*prevention & control
Inflammation/*prevention & control
Lipopolysaccharides/*toxicity
Neuroprotective Agents/*pharmacology
Adrenergic alpha-2 Receptor Agonists/pharmacology ; Animals ; Animals, Newborn ; Brain Injuries/chemically induced ; Brain Injuries/metabolism ; Brain Injuries/pathology ; Disease Models, Animal ; Female ; Gliosis/chemically induced ; Gliosis/metabolism ; Gliosis/pathology ; Inflammation/chemically induced ; Inflammation/metabolism ; Inflammation/pathology ; Male ; Pregnancy ; Rats ; Rats, Sprague-Dawley ; STAT3 Transcription Factor/genetics ; STAT3 Transcription Factor/metabolism
Contributed Indexing:
Keywords: Dexmedetomidine; Lipopolysaccharide; Myelination; Neurobehavioral deficits; Reactive astrogliosis
Substance Nomenclature:
0 (Adrenergic alpha-2 Receptor Agonists)
0 (Lipopolysaccharides)
0 (Neuroprotective Agents)
0 (STAT3 Transcription Factor)
0 (Stat3 protein, rat)
67VB76HONO (Dexmedetomidine)
Entry Date(s):
Date Created: 20201010 Date Completed: 20201230 Latest Revision: 20201230
Update Code:
20240105
DOI:
10.1016/j.lfs.2020.118556
PMID:
33038375
Czasopismo naukowe
Aims: White matter injury (WMI) is the main form of brain injury in preterm neonate survivors, and perinatal inflammation is implicated in the pathogenesis of WMI. It has been demonstrated that dexmedetomidine, an anesthetic adjuvant, possesses neuroprotective effects in both preclinical and clinical trials. The present study was conducted to explore whether dexmedetomidine could protect against neurobehavioral impairments and myelination deficits caused by lipopolysaccharide (LPS) exposure in the early postnatal rat brain.
Main Methods: LPS (2 mg/kg) was intraperitoneally (i.p.) injected in Sprague-Dawley rat pups on postnatal day 2 (P2). Dexmedetomidine (25 μg/kg) or vehicle was given i.p. immediately after LPS injection. STAT3 and p-STAT3 expression were detected by western blot in rat brain 24 h after drug administration. Immunostaining for GFAP to was performed to evaluate astrocytic response at 24 h post-LPS and P14. Neurobehavioral tests (the righting reflex, negative geotaxis, and wire hanging maneuver tests) were performed from P5 to P10. Histological analysis of myelin content was accessed by immunohistochemistry for CNPase and MBP at P14.
Key Findings: Our results showed that treatment with dexmedetomidine significantly ameliorated LPS-induced neurobehavioral abnormalities and myelin damage, which is accompanied by suppression of STAT3 activation and reactive astrogliosis.
Significance: Dexmedetomidine can alleviate neurobehavioral impairments and myelination deficits after LPS exposure in early postnatal rats, probably by mitigating STAT3-mediated reactive astrogliosis. Our results suggest that dexmedetomidine might be a promising agent to treat brain injury in neonates.
(Copyright © 2020 Elsevier Inc. All rights reserved.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies